Читать книгу Drug Transporters - Группа авторов - Страница 110

The mRNA level of SLC47A1 in human peripheral blood cells was previously found to be reflective of liver and kidney expression and predictive for drug‐induced liver injury to flutamide treatment for prostate cancer [126]. In the study, blood samples were obtained from Japanese patients (n = 52) prior to treatment and follow‐up of liver function enzymes (AST and ALT) was obtained for 6 months. Out of the 17 patients with elevations in liver enzymes, 15 had a >2‐fold decrease in SLC47A1 expression. The authors also conducted an experiment in Mate1 knockout mice showing elevated serum concentrations of a flutamide metabolite (4‐nitro‐3‐(trifluoromethyl)phenylamine). It was not reported whether the metabolite is a MATE1 substrate. The results suggest an association between MATE1 mRNA expression in blood and liver toxicity due to flutamide. A subsequent study in Japanese patients (n = 22) with prostate cancer evaluated SLC47A1 polymorphisms (rs2252281 and rs2453579) to determine whether mRNA expression in peripheral blood was associated with SLC47A1 genetics [127]. MATE1 mRNA levels were significantly greater in patients who were heterozygous for the rs2453579 and rs2252281 haplotype, suggesting the potential of a biomarker for predicting risk of liver injury secondary to flutamide. It is unclear, however, why the homozygous wild‐type and variant haplotypes both exhibited reduced expression, limiting the application of the results without further validation. Higher MATE1 expression in blood may be associated with organ levels and can be monitored for risk of flutamide toxicities.